Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
AssigneeInsmed Incorporated
InventorJimin Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for treating lupus nephritis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (INS1007).
Claims20
A method for treating lupus nephritis (LN) in a patient in need of treatment, comprising, administering to the patient a pharmaceutical composition comprising an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
- wherein,
- R1 is
- R2 is hydrogen, F, Cl, Br, OSO2C1-3alkyl, or C1-3alkyl;
- R3 is hydrogen, F, Cl, Br, CN, CF3, SO2C1-3alkyl, CONH2 or SO2NR4R5, wherein R4 and R5 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine or piperidine ring;
- or
- R6 is C1-3alkyl, optionally substituted by 1, 2 or 3 F and/or optionally by OH, OC1-3alkyl, N(C1-3alkyl)2, cyclopropyl, or tetrahydropyran;
- R7 is hydrogen, F, Cl or CH3;
- X is O, S or CF2;
- Y is O or S;
- and
- Q is CH or N.
Dependencies are inferred from the claim text.